Immuron (IMRN) Capital Expenditures (2016 - 2023)
Immuron (IMRN) posted quarterly Capital Expenditures of $292552.9 for Q2 2023, up 183.83% year-on-year from $103072.6 in Q2 2022, and up 4239.7% on a QoQ basis from -$7067.0 in Q4 2022.
Immuron (IMRN) Capital Expenditures (2016 - 2023) Analysis & Trends
Immuron (IMRN) has reported Capital Expenditures for 7 consecutive years, with $292552.9 the latest figure, recorded in Q2 2023.
- Quarterly Capital Expenditures rose 183.83% year-over-year to $292552.9 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was -$68172.4 (up 82.61% YoY) and the FY2025 annual result came in at -$3.0 million, down 1556965.64% from the prior year.
- Capital Expenditures improved to $292552.9 in Q2 2023 per IMRN's latest filing, from -$7067.0 in the prior quarter.
- Over the last five years, Capital Expenditures for IMRN reached as high as $292552.9 in Q2 2023 and fell as low as -$348976.0 in Q2 2022.
- A 5-year average of -$12015.6 and a median of -$5656.1 in 2020 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures sank 996.51% — and 2023, when it jumped 183.83%.
- Year by year, Capital Expenditures stood at -$864.0 in 2019, then slumped by 667.36% to -$6630.0 in 2020, then grew by 29.38% to -$4682.3 in 2021, then plunged by 50.93% to -$7067.0 in 2022, then surged by 4239.7% to $292552.9 in 2023.
- According to Business Quant data, Capital Expenditures over the past three periods registered $292552.9, -$7067.0, and -$348976.0 for Q2 2023, Q4 2022, and Q2 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Immuron | 270.20 Mn | 258.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 292,552.86 |
| Jun 30, 2023 | 292,552.86 |
| Dec 31, 2022 | -7,067.00 |
| Dec 31, 2022 | -7,067.00 |
| Jun 30, 2022 | -348,975.98 |
| Jun 30, 2022 | -348,975.98 |
| Dec 31, 2021 | -4,682.27 |
| Dec 31, 2021 | -4,682.27 |
| Jun 30, 2021 | -31,826.01 |
| Jun 30, 2021 | -31,826.01 |
| Dec 31, 2020 | -6,630.00 |
| Dec 31, 2020 | -6,630.00 |
| Jun 30, 2020 | 11,367.39 |
| Jun 30, 2020 | 11,367.39 |
| Dec 31, 2019 | -864.00 |
| Dec 31, 2019 | -864.00 |
| Dec 31, 2017 | -2,180.00 |
| Dec 31, 2017 | -2,180.00 |
| Dec 31, 2016 | 1,327.00 |
| Dec 31, 2016 | 1,327.00 |